JP2020513829A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513829A5
JP2020513829A5 JP2019552109A JP2019552109A JP2020513829A5 JP 2020513829 A5 JP2020513829 A5 JP 2020513829A5 JP 2019552109 A JP2019552109 A JP 2019552109A JP 2019552109 A JP2019552109 A JP 2019552109A JP 2020513829 A5 JP2020513829 A5 JP 2020513829A5
Authority
JP
Japan
Prior art keywords
vector
domain
cell
group
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019552109A
Other languages
English (en)
Japanese (ja)
Other versions
JP7137896B2 (ja
JP2020513829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/024183 external-priority patent/WO2018175988A1/en
Publication of JP2020513829A publication Critical patent/JP2020513829A/ja
Publication of JP2020513829A5 publication Critical patent/JP2020513829A5/ja
Priority to JP2022139092A priority Critical patent/JP7448896B2/ja
Application granted granted Critical
Publication of JP7137896B2 publication Critical patent/JP7137896B2/ja
Priority to JP2024021341A priority patent/JP7808628B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019552109A 2017-03-24 2018-03-23 抗cd33免疫療法によりがんを処置するための組成物および方法 Active JP7137896B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022139092A JP7448896B2 (ja) 2017-03-24 2022-09-01 抗cd33免疫療法によりがんを処置するための組成物および方法
JP2024021341A JP7808628B2 (ja) 2017-03-24 2024-02-15 抗cd33免疫療法によりがんを処置するための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762476438P 2017-03-24 2017-03-24
US62/476,438 2017-03-24
US201862620139P 2018-01-22 2018-01-22
US62/620,139 2018-01-22
PCT/US2018/024183 WO2018175988A1 (en) 2017-03-24 2018-03-23 Compositions and methods for treating cancer with anti-cd33 immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022139092A Division JP7448896B2 (ja) 2017-03-24 2022-09-01 抗cd33免疫療法によりがんを処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020513829A JP2020513829A (ja) 2020-05-21
JP2020513829A5 true JP2020513829A5 (enExample) 2021-03-11
JP7137896B2 JP7137896B2 (ja) 2022-09-15

Family

ID=62090025

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019552109A Active JP7137896B2 (ja) 2017-03-24 2018-03-23 抗cd33免疫療法によりがんを処置するための組成物および方法
JP2022139092A Active JP7448896B2 (ja) 2017-03-24 2022-09-01 抗cd33免疫療法によりがんを処置するための組成物および方法
JP2024021341A Active JP7808628B2 (ja) 2017-03-24 2024-02-15 抗cd33免疫療法によりがんを処置するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022139092A Active JP7448896B2 (ja) 2017-03-24 2022-09-01 抗cd33免疫療法によりがんを処置するための組成物および方法
JP2024021341A Active JP7808628B2 (ja) 2017-03-24 2024-02-15 抗cd33免疫療法によりがんを処置するための組成物および方法

Country Status (7)

Country Link
US (3) US10426797B2 (enExample)
EP (1) EP3601356A1 (enExample)
JP (3) JP7137896B2 (enExample)
CN (2) CN112695050B (enExample)
AU (2) AU2018240556B2 (enExample)
CA (1) CA3057838A1 (enExample)
WO (1) WO2018175988A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3184548A1 (en) 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
CN109843922B (zh) 2016-09-02 2023-10-03 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
WO2018175988A1 (en) 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
KR102845789B1 (ko) 2017-11-01 2025-08-14 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
MX2021005024A (es) * 2018-11-01 2021-07-21 Juno Therapeutics Inc Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
EP3876961A4 (en) * 2018-11-06 2023-01-25 Washington University CHIMERIC ANTIGEN RECEPTOR MEMORY-LIKE (CARML) NK CELLS AND METHODS FOR THEIR PRODUCTION AND USE
EP3883971A1 (en) 2019-01-22 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
US11969443B2 (en) * 2019-03-06 2024-04-30 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
CA3133333A1 (en) 2019-04-30 2020-04-30 Brian Scott GARRISON Chimeric receptors and methods of use thereof
KR20220004750A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. Cd33 결합 폴리펩타이드 및 이의 용도
EP3966251A4 (en) * 2019-05-08 2023-05-10 Inhibrx, Inc. IMMUNOTHERAPIES TARGETED AGAINST CD33
CN113150167A (zh) * 2020-01-22 2021-07-23 中国人民解放军总医院第五医学中心 一种能够反转pd-1免疫抑制信号的car t细胞结构em1设计
CA3172691A1 (en) * 2020-03-31 2021-10-07 Cameron J. Turtle Chimeric antigen receptors targeting cd33
CN111848819A (zh) * 2020-07-31 2020-10-30 广东昭泰体内生物医药科技有限公司 一种靶向msln的嵌合抗原受体及其应用
JP2024540360A (ja) * 2021-11-09 2024-10-31 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ グリピカン-3(GPC3)を標的にするIgG4ヒンジ含有キメラ抗原受容体およびその使用
CN114133457B (zh) * 2021-12-08 2022-08-19 郑州源创吉因实业有限公司 一种靶向ror1和cd33的双特异性嵌合抗原受体(car)及其应用
AU2023314413A1 (en) 2022-07-28 2025-02-13 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20240075142A1 (en) 2022-08-26 2024-03-07 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
CN121666232A (zh) 2023-05-31 2026-03-13 开普斯坦治疗公司 脂质纳米颗粒制剂和组合物
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025090985A1 (en) * 2023-10-27 2025-05-01 Duke University Compositions comprising chimeric antigen receptors targeting citrullinated vimentin and methods of use thereof
WO2025096878A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics, Inc. Rna for in vivo transfection with increased expression
US20250332281A2 (en) 2023-12-15 2025-10-30 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
US20260000765A1 (en) 2024-06-27 2026-01-01 Lentigen Technology, Inc. CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS
CN120485285A (zh) * 2025-07-18 2025-08-15 天津医科大学总医院 一种质粒载体、嵌合mog抗体受体t细胞及其应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060165A (en) 1962-10-23 Preparation of toxic ricin
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5208021A (en) 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗hiv剤
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
EP0973540B1 (en) 1997-02-25 2005-11-02 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
WO2008143702A2 (en) * 2006-12-01 2008-11-27 Duke University Anti-mrp3 antibodies and methods of use
EP2480230A4 (en) 2009-09-24 2015-06-10 Seattle Genetics Inc DR5 Ligand-HEILMITTELKONJUGATE
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
WO2011106723A2 (en) 2010-02-26 2011-09-01 Lpath, Inc. Anti-paf antibodies
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6307085B2 (ja) * 2012-09-27 2018-04-04 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズThe United States of America,as represented by the Secretary,Department of Health and Human Services メソテリン抗体および強力な抗腫瘍活性を惹起するための方法
JP6338252B2 (ja) * 2012-10-24 2018-06-06 アメリカ合衆国 M971キメラ抗原受容体
US20140186365A1 (en) * 2013-01-03 2014-07-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
AU2015239069B2 (en) * 2014-04-03 2020-02-20 Cellectis CD33 specific Chimeric Antigen Receptors for cancer immunotherapy
SG10201913765YA (en) * 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
MX2017001079A (es) * 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
GB201507104D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN108603170A (zh) * 2015-06-12 2018-09-28 莱蒂恩技术公司 用工程改造的t细胞治疗癌症的方法
CN104877032B (zh) * 2015-06-26 2018-12-11 中国医学科学院血液病医院(血液学研究所) Cd33特异性嵌合抗原受体及其应用
US20180311374A1 (en) * 2015-10-30 2018-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Targeted cancer therapy
CN105820255B (zh) * 2016-04-12 2019-06-28 上海优卡迪生物医药科技有限公司 抗cd33嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
CN109843922B (zh) * 2016-09-02 2023-10-03 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
WO2018175988A1 (en) * 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy

Similar Documents

Publication Publication Date Title
JP2020513829A5 (enExample)
JP2020533958A5 (enExample)
JP2021500881A5 (enExample)
JP2022113880A5 (enExample)
FI3823665T3 (fi) BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä
JP2020513754A5 (enExample)
JPWO2020061498A5 (enExample)
JP2018515123A5 (enExample)
JP2020517295A5 (enExample)
JP2019536452A5 (enExample)
JP2017524367A5 (enExample)
JP2021502070A5 (enExample)
EP3829312A1 (en) Multi-function and multi-targeting car system and methods for use thereof
HRP20231542T1 (hr) Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe
JP2019537433A5 (enExample)
JP2016514462A5 (enExample)
JPWO2020018825A5 (enExample)
JPWO2021102337A5 (enExample)
JP2017519502A5 (enExample)
JP2025060882A5 (enExample)
JPWO2020069184A5 (enExample)
JPWO2021061778A5 (enExample)
CN111479925A (zh) 具有y182t突变的t细胞-抗原偶联物及其方法和用途
CN112442509A (zh) Cd19-cd20双特异性和双通道car-t及其使用方法
JPWO2020181164A5 (enExample)